The Advanced Prostate Cancer Consensus Conference held in 2019 supported consideration of BRCA1 and BRCA2 testing in screening, management, and informing prognosis/treatment, with germline testing recommended in patients with a tumour BRCA1, BRCA2, or ATM mutation [38]. This evidence concerns the gene BRCA2 and prostate cancer.